Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.
作者信息
Sudhan Dhivya R, Guerrero-Zotano Angel, Won Helen, Ericsson Paula González, Servetto Alberto, Huerta-Rosario Mariela, Ye Dan, Lee Kyung-Min, Formisano Luigi, Guo Yan, Liu Qi, Kinch Lisa N, Brewer Monica Red, Dugger Teresa, Koch James, Wick Michael J, Cutler Richard E, Lalani Alshad S, Bryce Richard, Auerbach Alan, Hanker Ariella B, Arteaga Carlos L
出版信息
Cancer Cell. 2020 Feb 10;37(2):258-259. doi: 10.1016/j.ccell.2020.01.010.
Abstract
摘要
相似文献
1
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.TORC1的过度激活导致HER2突变型癌症对泛HER酪氨酸激酶抑制剂奈拉替尼产生耐药性。
Cancer Cell. 2020 Feb 10;37(2):258-259. doi: 10.1016/j.ccell.2020.01.010.
2
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.TORC1 的过度激活导致 HER2 突变型癌症对泛 HER 酪氨酸激酶抑制剂奈拉替尼产生耐药性。
Cancer Cell. 2020 Feb 10;37(2):183-199.e5. doi: 10.1016/j.ccell.2019.12.013. Epub 2020 Jan 23.
3
Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.来那替尼在HER2阳性乳腺癌及HER2突变乳腺癌中的药效学、药代动力学及临床疗效
Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):947-57. doi: 10.1080/17425255.2016.1198317. Epub 2016 Jun 27.
4
Neratinib for the treatment of breast cancer.奈拉替尼用于治疗乳腺癌。
Expert Opin Pharmacother. 2016 Nov;17(16):2243-2248. doi: 10.1080/14656566.2016.1244528. Epub 2016 Oct 17.
5
New protein kinase inhibitors in breast cancer: afatinib and neratinib.乳腺癌中的新型蛋白激酶抑制剂：阿法替尼和来那替尼。
Expert Opin Pharmacother. 2014 Jun;15(9):1277-88. doi: 10.1517/14656566.2014.913570. Epub 2014 Apr 30.
6
The role of neratinib in HER2-driven breast cancer.奈拉替尼在HER2驱动的乳腺癌中的作用。
Future Oncol. 2017 Sep;13(22):1931-1943. doi: 10.2217/fon-2017-0186. Epub 2017 Jun 30.
7
Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.奈拉替尼，一种新型的HER2靶向酪氨酸激酶抑制剂。
Clin Breast Cancer. 2016 Oct;16(5):344-348. doi: 10.1016/j.clbc.2016.05.016. Epub 2016 May 29.
8
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.Neratinib 联合替西罗莫司治疗人表皮生长因子受体 2 依赖性和其他实体瘤患者的 I 期研究。
J Clin Oncol. 2014 Jan 10;32(2):68-75. doi: 10.1200/JCO.2012.47.2787. Epub 2013 Dec 9.
9
Anti-tumor activity of neratinib, a pan-HER inhibitor, in gastric adenocarcinoma cells.奈拉替尼（pan-HER 抑制剂）对胃腺癌细胞的抗肿瘤活性。
Eur J Pharmacol. 2019 Nov 15;863:172705. doi: 10.1016/j.ejphar.2019.172705. Epub 2019 Sep 28.
10
Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2 breast cancer metastasis.新辅助奈拉替尼促进铁死亡并抑制自发 HER2 乳腺癌转移的新型同源模型中的脑转移。
Breast Cancer Res. 2019 Aug 13;21(1):94. doi: 10.1186/s13058-019-1177-1.
引用本文的文献
1
Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations.泛ErbB抑制剂neratinib与mTOR抑制剂依维莫司联合用于ErbB家族基因改变的晚期癌症患者的I期试验。
ESMO Open. 2025 Feb;10(2):104136. doi: 10.1016/j.esmoop.2025.104136. Epub 2025 Feb 4.
2
The uncharted role of HER2 mutant alleles in breast cancer.HER2 突变等位基因在乳腺癌中的未知作用。
Oncotarget. 2023 Oct 31;14:904-907. doi: 10.18632/oncotarget.28489.
3
Neratinib for HER2-positive breast cancer with an overlooked option.奈拉替尼用于 HER2 阳性乳腺癌：被忽视的选择。
Mol Med. 2023 Oct 6;29(1):134. doi: 10.1186/s10020-023-00736-0.
4
Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2 breast cancer by ceramide-loaded nanoparticles.混合谱系激酶 3 和 CD70 合作通过载神经酰胺纳米颗粒使曲妥珠单抗耐药的 HER2 乳腺癌敏感。
Proc Natl Acad Sci U S A. 2022 Sep 20;119(38):e2205454119. doi: 10.1073/pnas.2205454119. Epub 2022 Sep 12.
5
Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer.波齐替尼抑制 HER2 突变驱动的治疗耐药性和乳腺癌多器官转移。
Cancer Res. 2022 Aug 16;82(16):2928-2939. doi: 10.1158/0008-5472.CAN-21-3106.
6
Overexpressed p-S6 associates with lymph node metastasis and predicts poor prognosis in non-small cell lung cancer.过度表达的 p-S6 与非小细胞肺癌的淋巴结转移相关，并预测不良预后。
BMC Cancer. 2022 May 20;22(1):564. doi: 10.1186/s12885-022-09664-4.
7
ZDHHC22-mediated mTOR palmitoylation restrains breast cancer growth and endocrine therapy resistance.ZDHHC22 介导的 mTOR 棕榈酰化抑制乳腺癌生长和内分泌治疗耐药性。
Int J Biol Sci. 2022 Apr 4;18(7):2833-2850. doi: 10.7150/ijbs.70544. eCollection 2022.
8
Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer.阻断 ErbB-2 异构体逆行运输至细胞核作为三阴性乳腺癌的一种新的治疗策略。
Cell Death Dis. 2022 May 9;13(5):447. doi: 10.1038/s41419-022-04855-0.
9
A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations.一种针对HER2突变的HR+/HER2-晚期乳腺癌患者的新型治疗策略，即HER2靶向治疗联合依维莫司。
Transl Oncol. 2022 Jul;21:101444. doi: 10.1016/j.tranon.2022.101444. Epub 2022 May 3.
10
New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumor growth, therapeutic resistance and steroidogenesis.靶向酰基辅酶 A 合成酶 4 的新型抑制剂可减少乳腺和前列腺肿瘤生长、治疗抵抗和类固醇生成。
Cell Mol Life Sci. 2021 Mar;78(6):2893-2910. doi: 10.1007/s00018-020-03679-5. Epub 2020 Oct 17.
Zotero 插件